SAB Biotherapeutics (SABS) Revenue (2021 - 2024)

SAB Biotherapeutics (SABS) has 4 years of Revenue data on file, last reported at $114698.0 in Q4 2024.

• Quarterly Revenue fell 62.4% year-over-year to $114698.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.3 million (down 40.94% YoY) and the FY2024 annual result came in at $1.3 million, down 40.94% from the prior year.
• Revenue slipped to $114698.0 in Q4 2024, from $263137.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $18.2 million in Q2 2021 to a low of $85518.0 in Q2 2023.
• A 4-year average of $5.9 million and a median of $2.2 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue sank 98.65% — and 2024, when it surged 207.7%.
• Tracing SABS's Revenue over 4 years: stood at $11.1 million in 2021, then slumped by 80.46% to $2.2 million in 2022, then tumbled by 85.88% to $305011.0 in 2023, then tumbled by 62.4% to $114698.0 in 2024.
• The last three Revenue figures came in at $114698.0 (Q4 2024), $263137.0 (Q2 2024), and $944575.0 (Q1 2024), per Business Quant data.